Stockscreener 앱 받기
27.52
3.07%
0.82
시간 외 거래:
27.52
전일 마감가:
$26.70
열려 있는:
$27.28
하루 거래량:
647.16K
Relative Volume:
0.95
시가총액:
$1.58B
수익:
$32.87M
순이익/손실:
$674.31M
주가수익비율:
2.4225
EPS:
11.36
순현금흐름:
$-330.11M
1주 성능:
+6.25%
1개월 성능:
-11.02%
6개월 성능:
-33.33%
1년 성능:
-6.74%
1일 변동 폭
$26.23
$27.71
1주일 범위
$23.41
$27.71
52주 변동 폭
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
27.52 | 1.58B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.83 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.06 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
606.39 | 36.98B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.01 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
242.75 | 26.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-27 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock By Investing.com - Investing.com South Africa
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock - Investing.com India
Agios Pharmaceuticals Director Sells Shares to Cover Tax Obligations - TradingView
Agios stock touches 52-week low at $24.33 amid market challenges - Investing.com Australia
Agios stock touches 52-week low at $24.33 amid market challenges By Investing.com - Investing.com South Africa
Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says - MarketScreener
Agios stock touches 52-week low at $27.12 amid market shifts - Investing.com India
Agios stock touches 52-week low at $27.12 amid market shifts By Investing.com - Investing.com South Africa
Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
Agios Pharmaceuticals develops PAH mutant stabilizers for phenylketonuria - BioWorld MedTech
First Week of November 21st Options Trading For Agios Pharmaceuticals (AGIO) - Nasdaq
Agios Pharmaceuticals divulges new PAH stabilizers for phenylketonuria - BioWorld MedTech
Beta Thalassemia Market Predicted to See Upsurge Through 2034, - openPR
Agios Pharmaceuticals at Barclays Conference: Strategic Advances in Rare Disease Treatments - Investing.com UK
Agios Pharm at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com Canada
Q1 EPS Estimate for Agios Pharmaceuticals Lowered by Analyst - Defense World
FY2027 Earnings Estimate for AGIO Issued By Zacks Research - Defense World
Agios Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer - The Manila Times
Agios Pharmaceuticals Announces Inducement Equity Awards for New Executive - GuruFocus.com
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate - EIN News
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences - Barchart
Meet Agios' New Strategy Chief: Inside the $2M+ Executive Compensation Deal - Stock Titan
Agios Pharmaceuticals chief commercial officer sells $59,742 in stock By Investing.com - Investing.com South Africa
Agios Pharmaceuticals chief commercial officer sells $59,742 in stock - Investing.com India
Agios Pharmaceuticals CEO sells shares worth $460,135 - Investing.com
Agios to Present at Upcoming Investor Conferences - The Manila Times
Where to Hear Agios Management Next Month: Key Investor Conferences Revealed - StockTitan
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune
Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now? - Insider Monkey
Y Intercept Hong Kong Ltd Acquires Shares of 45,817 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
What is HC Wainwright's Estimate for AGIO Q1 Earnings? - MarketBeat
Earnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock rises - MSN
10 Best Small-Cap Stocks to Buy Now - Insider Monkey
Gilbert Cisneros conducts multiple transactions in stocks including Agios Pharmaceuticals and Airbnb - MSN
Sickle Cell Disease Market Growth Projections 2024-2034: - openPR
Q4 Earnings Estimate for AGIO Issued By HC Wainwright - MarketBeat
Venturi Wealth Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
What is HC Wainwright’s Estimate for AGIO Q4 Earnings? - Defense World
Agios Bolsters Coffers With $1.1 Bln Milestone Payments Following FDA Approval Of Vorasidenib - RTTNews
H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright starts Agios Pharmaceuticals coverage with 'buy' - TradingView
H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating - Investing.com India
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 6.0% in January - MarketBeat
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 - The Manila Times
Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem - Simply Wall St
Rare Disease Leader Agios Takes Center Stage at Major Healthcare ConferenceKey Details Inside - StockTitan
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.com to "Sell" - MarketBeat
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.71%
자본화:
|
볼륨(24시간):